State Street Corp Mustang Bio, Inc. Transaction History

State Street Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.58 - $1.13 $703,839 - $1.37 Million	-1,213,517 Reduced 83.47%	240,274 $141,000
Q1 2022 May 16, 2022	SELL	$0.73 - $1.81 $1,390 - $3,448	-1,905 Reduced 0.13%	1,453,791 $1.47 Million
Q4 2021 Feb 14, 2022	BUY	$1.66 - $2.64 $45,274 - $72,003	27,274 Added 1.91%	1,455,696 $2.42 Million
Q3 2021 Nov 15, 2021	BUY	$2.58 - $3.36 $1.08 Million - $1.4 Million	417,148 Added 41.25%	1,428,422 $3.84 Million
Q2 2021 Aug 16, 2021	BUY	$2.7 - $3.81 $828,179 - $1.17 Million	306,733 Added 43.54%	1,011,274 $3.36 Million
Q1 2021 May 17, 2021	BUY	$3.02 - $5.16 $164,167 - $280,497	54,360 Added 8.36%	704,541 $2.34 Million
Q4 2020 Feb 16, 2021	BUY	$2.66 - $4.18 $334,481 - $525,614	125,745 Added 23.98%	650,181 $2.46 Million
Q3 2020 Nov 10, 2020	BUY	$3.01 - $3.88 $76,297 - $98,350	25,348 Added 5.08%	524,436 $1.65 Million
Q2 2020 Aug 14, 2020	BUY	$2.33 - $4.6 $17,328 - $34,210	7,437 Added 1.51%	499,088 $1.59 Million
Q1 2020 May 11, 2020	BUY	$1.91 - $4.52 $939,053 - $2.22 Million	491,651 New	491,651 $1.32 Million

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $27.4M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.